ARTICLES| VOLUME 20, ISSUE 10, P1161-1171, OCTOBER 01, 2020 Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study Yang Wang, Chunyan Xu, Rong Zhang, et al Lancet Infect Dis 2020; 20: 1161-1171 Summary 摘要 Background 背景 Following the discovery and emergence of the plasmid-mediated colistin resistance gene, mcr-1, ...

Treating Early COVID-19 Infection There have been over 47 million cases of COVID-19 globally and 1.2 million deaths. According to Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), the treatment of patients with early COVID-19 infection requires urgent focus. Treating these patients early in the course of infection could help speed up their recovery and could also reduce the likelihood of severe outcomes. Early treatment would...

Editor's Note November 12, 2020 COVID-19 Infection—Preventing Clinical Deterioration Christopher W. Seymour, Howard Bauchner, Robert M. Golub JAMA. Published online November 12, 2020. doi:10.1001/jama.2020.21720 More than 38 million individuals worldwide have been infected with severe acute respiratory syndrome coronavirus 2, the virus causing coronavirus disease 2019 (COVID-19). For primary prevention, traditional public health approaches inclu...

Life After COVID-19 Hospitalisation Findings from a new study show that surviving a case of COVID-19 that is severe enough to require hospitalisation can be quite challenging, but life after the ICU stay is also not a bed of roses.  The study includes data from 1250 patients treated in 38 hospitals. The average age of the participants is 62 years, and 83% of the patients lived at home after being hospitalised for COVID-19.  The study reports that approximately 7%...

ORIGINAL ARTICLE Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 John H. Stone, Matthew J. Frigault, Naomi J. Serling-Boyd, et al N Engl J Med 2020; 383:2333-2344DOI: 10.1056/NEJMoa2028836 Abstract BACKGROUND The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear. METHODS We performed a randomized, double-blind, placebo-...

Improving Outcomes for ICU Survivors In response to the many challenges faced by ICU survivors today, there has been an increasing need to relieve this burden. Despite that many clinical trials have been implemented to find new strategies, postintensive care syndrome is still a common possibility for both patients and families. A recent study has identified key enablers and barriers faced by hospitals and patients when implementing ICU follow-up clinics and peer sup...

Preliminary Communication November 12, 2020 Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial Eric J. Lenze, Caline Mattar, Charles F. Zorumski, et al JAMA. Published online November 12, 2020. doi:10.1001/jama.2020.22760 Abstract Importance Coronavirus disease 2019 (COVID-19) may lead to serious illness as a result of an excessive immune response. Fluvoxamine may prevent...

Early Prediction of Sepsis From Clinical Data Sepsis continues to be a leading cause of death in hospitalised patients. Approximately 1.7 million individuals develop sepsis each year in the US and of these, around 270,000 die from the infection. Sepsis affects nearly 30 million patients worldwide and nearly 6 million die from sepsis each year. Billions of dollars are required to manage sepsis, far exceeding the cost of most other healthcare disorders. Sepsis is trea...

Viewpoint October 26, 2020 Preventing the Spread of SARS-CoV-2 With Masks and Other “Low-tech” Interventions Andrea M. Lerner, Gregory K. Folkers, Anthony S. Fauci JAMA. 2020;324(19):1935-1936. doi:10.1001/jama.2020.21946 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has caused a global pandemic of historic proportions in the 10 months since cases were first reported in Wuhan, China, in Dec...

BLAZE Trial: Efficacy and Safety of LY-CoV555 COVID-19 patients can have a wide range of disease severity, with some patients experiencing only mild symptoms while others are infected quite severely. However, approximately 10% of asymptomatic and mild cases lead to severe outcomes, including respiratory distress that would require hospitalisation. Many risk factors for severe disease have been proposed, including old age, obesity, hypertension and underlying medic...